Evidence map›Paper›PMID 40772783›Full record

Observational studyFuture oncology (London, England)2025

Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study.

José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

José A ArranzDepartment of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Cristina MartínezDepartment of Oncology, IQVIA, Madrid, Spain.
Lucía GallegoDepartment of Real-World Evidence, IQVIA, Madrid, Spain.
Ana HerederoDepartment of Oncology, IQVIA, Madrid, Spain.
Pablo RebolloDepartment of Real-World Evidence, IQVIA, Madrid, Spain.
Laura FernándezDepartment of Medical Affairs, Bristol Myers Squibb, Madrid, Spain.
Elvira EstellaDepartment of Market Access, Bristol Myers Squibb, Madrid, Spain.
David Vilanova LarenaReal World Evidence and Outcomes Research, Market Access Departement, Bristol Myers Squibb, Madrid, Spain.
Virginia PalomarDepartment of Medical Affairs, Bristol Myers Squibb, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAdvanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.

methodWe conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.

resultsA total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.

conclusionsDuring this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsPractice Patterns, Physicians'AdultAgedCross-Sectional StudiesFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedPrognosisProtein Kinase InhibitorsSpainImmune Checkpoint InhibitorsProtein Kinase Inhibitorsadvanced renal cell carcinomaclinical practiceimmunotherapynivolumabOncologyoncology dynamicsreal-world evidencetyrosine kinase inhibitors

Identifiers

PMID40772783
PMCPMC12407652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.